Holistic understanding of patients
Diagnostics standardization
Pathology empowerment
Proactive R&D approach
Strategies to help pharma deliver n=1 care
Continue using innovative trial designs supplemented by
well-sourced real-world evidence (RWE).
Collaborate with industry stakeholders to eliminate data silos
and establish standards for collecting and using RWE in
drug discovery.
Engage with regulatory agencies earlier to navigate logistical and design challenges.
Support infrastructure for HCPs
Work with diagnostic companies and payers to drive greater standardization of testing. This would likely require working with payers or policymakers, with leadership from pharma.
Work with other pharma companies on education and marketing efforts for diagnostics and products that target the same biomarkers or possess similar indications.
Push for dedicated diagnostic codes and clear tracking of testing to enable greater visibility for payers.
Empower pathologists to influence payers and public policy coverage decisions.
Anchor towards innovative agreements that share the risk of innovation with payers.
Integrate conventional and nonconventional data that can
assist physicians with patient identification and timely
medical interventions.
Push for availability of clinical decision support tools, including comparison of diagnostic tests and integration of diagnostic test results into electronic health records.
Encourage use of virtual tumor boards, digital pathology
and telemedicine.
Invest in developing a holistic understanding of patients that spans longer periods of their lives, based on learnings from running trials.
Use direct-to-consumer strategies to get patients to think holistically about their health.
•
•
•
•
•
•
•
•
•
•
•
•
•
